14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
GBIO vs AVDL
Tradestie Institutional Equity Comparison Engine · Market Close Feb 11, 2026
GBIO vs AVDL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVDL Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–2 Matrix Metrics)
AVDL Overall Winner
6-Pillar Tally: GBIO 1 – 3 AVDL (2 Tie)
Matrix Metrics: GBIO 2 – 7 AVDL
As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GBIO carries a Unified Composite Score of 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).
GBIO
NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
Market Cap
$38.7M
TTM Revenue
$15M
Forward P/E
7.9x
Beta / 30D Vol
0.80β · 26% Vol
Unified Composite Score
58.8 / 100
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 53.9
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $5.61 · SMA50: $5.49
AVDL
NASDAQ
Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
Market Cap
$2.1B
TTM Revenue
$249M
Forward P/E
28.8x
Beta / 30D Vol
0.14β · 2% Vol
Unified Composite Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
6-Pillar Scorecard Institutional Category Breakdown (GBIO 1 – 3 AVDL)
Columns: Metric · GBIO · AVDL
1. Valuation Multiples
GBIO
Forward P/E
7.9x
28.8x
Trailing P/E
7.9x
16.8x
PEG Ratio
N/M
0.07x
EV / Revenue
2.5x
8.5x
2. Growth & Scale
AVDL
Revenue Growth (YoY)
-78.9%
+54.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$15M
$249M
Market Cap
$38.7M
$2.1B
3. Profitability & Quality
AVDL
Gross Margin
N/A
94.9%
Operating Margin
-2020.0%
2.5%
Net Profit Margin
0.0%
-0.1%
Return on Equity (ROE)
-80.8%
-0.3%
4. Balance Sheet & Cash Flow
AVDL
Cash Generation (TTM)
-$76M EBITDA
$2.7M EBITDA
Cash Flow Margin
N/A
1.1% EBITDA Mgn
Net Cash / Leverage
$7.51 Book/Sh · -80.8% ROE
$1.01 Book/Sh · -0.3% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
2.4% (<1st %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: GBIO (2) vs AVDL (7)
Institutional Metric
GBIO
AVDL
Criterion
Row Edge
Market Capitalization
Scale
$38.7M
$2.1B
Larger Scale
AVDL
Trailing P/E Ratio
Valuation
7.9x
16.8x
Lower Multiple
GBIO
Forward P/E Ratio
Valuation
7.9x
28.8x
Lower Multiple
GBIO
Revenue Growth (YoY)
Growth
-78.9%
+54.9%
Higher Growth
AVDL
Operating Margin (TTM)
Profitability
-2020.0%
2.5%
Higher Margin
AVDL
Net Profit Margin
Profitability
0.0%
-0.1%
Higher Margin
Tie
Return on Equity (ROE)
Capital Efficiency
-80.8%
-0.3%
Higher ROE
AVDL
52-Week Range Position
Momentum
62% ($0–$8)
89% ($6–$24)
Stronger Trend
AVDL
Beta / 30D Volatility
Risk Regime
0.80β · 26% Vol
0.14β · 2% Vol
Lower Realized Risk
AVDL
Unified Institutional Score
Composite Signal
58.8 / 100 (HOLD)
62.9 / 100 (BUY)
Higher Composite
AVDL
Trailing 12M Revenue (USD)
Operating Scale
$15M
$249M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
94.9%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.5x EV/Rev
0.07x PEG · 8.5x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$76M EBITDA ($7.51 Book/Sh · -80.8% ROE)
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
AVDL +3.26 pp
GBIO:
-2.38%
·
AVDL:
+0.88%
3M Horizon
AVDL +11.51 pp
GBIO:
+2.89%
·
AVDL:
+14.4%
6M Horizon
AVDL +41.58 pp
GBIO:
+28.67%
·
AVDL:
+70.25%
1Y Horizon
AVDL +162.32 pp
GBIO:
-23.71%
·
AVDL:
+138.61%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GBIO vs AVDL. Trailing 12-month operating profitability (GBIO -2020.0% vs AVDL 2.5%) and valuation multiples (GBIO 7.9x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
GBIO ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $15M
Gross Margin N/A
Op. Margin -2020.0%
ROE / Fwd P/E -80.8% · 7.9x
AVDL ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $249M
Gross Margin 94.9%
Op. Margin 2.5%
ROE / Fwd P/E -0.3% · 28.8x
GBIO
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
AVDL
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
2.4%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
GBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $38.7M market capitalization and -2020.0% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
AVDL Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ GBIO vs AVDL Key Questions & Quantitative Answers
Is GBIO or AVDL a better stock to buy right now?
As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GBIO carries a Unified Composite Score of 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Technically, GBIO sits in a Neutral phase (RSI 39.7, UNCLASSIFIED options structure) and AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure).
Does GBIO or AVDL have stronger revenue and earnings growth?
AVDL leads the Growth & Scale pillar: GBIO posts -78.9% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (N/A gross margin, -2020.0% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, GBIO generates $15M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, GBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.
Is GBIO or AVDL cheaper on valuation?
GBIO screens cheaper on headline valuation multiples. GBIO trades at 7.9x Forward P/E, 7.9x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported EBITDA margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GBIO (-80.8% ROE) versus AVDL (-0.3% ROE) capital efficiency.
How is options market volatility positioned on GBIO vs AVDL?
In options market volatility and institutional positioning, GBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 26% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).
Generation Bio Co. Common Stock (GBIO) Research Suite
Avadel Pharmaceuticals plc Ordinary Share (AVDL) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 11, 2026. For educational research only; not investment advice.